Jason D Marshall

Summary

Affiliation: Dynavax Technologies
Country: USA

Publications

  1. ncbi request reprint Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California, USA
    J Leukoc Biol 73:781-92. 2003
  2. ncbi request reprint Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California, USA
    J Leukoc Biol 82:497-508. 2007
  3. pmc Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunology 117:38-46. 2006
  4. ncbi request reprint Superior activity of the type C class of ISS in vitro and in vivo across multiple species
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California 94710, USA
    DNA Cell Biol 24:63-72. 2005
  5. ncbi request reprint Polymyxin B enhances ISS-mediated immune responses across multiple species
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, CA, USA
    Cell Immunol 229:93-105. 2004
  6. ncbi request reprint A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production
    Karen Fearon
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 33:2114-22. 2003
  7. pmc Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells
    Jason D Marshall
    Dynavax Technologies Corporation, 717 Potter Street, Suite 100, Berkeley, CA 94710, USA
    Nucleic Acids Res 31:5122-33. 2003
  8. ncbi request reprint IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
    Omar Duramad
    Dynavax Technologies, 717 Potter St, Ste 100, Berkeley, CA 94710, USA
    Blood 102:4487-92. 2003
  9. ncbi request reprint Immunostimulatory DNA as a vaccine adjuvant
    Debbie Higgins
    Preclinical Research, Dynavax Technologies, 2929 Seventh Street, Suite 100, Berkeley, CA 94710, USA
    Expert Rev Vaccines 6:747-59. 2007
  10. ncbi request reprint CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells
    Nicholas M Ponzio
    Department of Pathology and Laboratory Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School and Graduate School of Biomedical Sciences, Newark, NJ 07107, United States
    Int Immunopharmacol 6:2057-68. 2006

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California, USA
    J Leukoc Biol 73:781-92. 2003
    ....
  2. ncbi request reprint Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California, USA
    J Leukoc Biol 82:497-508. 2007
    ....
  3. pmc Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Immunology 117:38-46. 2006
    ..These results illustrate an important function for type I interferon in innate immunity, which is not only to activate effectors like NK cells directly, but also to prime them for enhanced activation by other factors such as TNF-alpha...
  4. ncbi request reprint Superior activity of the type C class of ISS in vitro and in vivo across multiple species
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, California 94710, USA
    DNA Cell Biol 24:63-72. 2005
    ..In conclusion, we have shown CpG-C to exert several types of immune functions across multiple species, and this novel class is thus an attractive candidate for ISS-based therapeutic strategies...
  5. ncbi request reprint Polymyxin B enhances ISS-mediated immune responses across multiple species
    Jason D Marshall
    Dynavax Technologies Corporation, Berkeley, CA, USA
    Cell Immunol 229:93-105. 2004
    ..These data illustrate the usefulness of formulating ISS with a cationic lipopeptide such as PMXB, which focuses and greatly amplifies the ISS-induced pathway of IFN-alpha-mediated responses...
  6. ncbi request reprint A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production
    Karen Fearon
    Dynavax Technologies Corporation, Berkeley, CA 94710, USA
    Eur J Immunol 33:2114-22. 2003
    ..These results describe a novel technique for formulating active, but very short, ISS oligodeoxynucleotide that allows for the dissection and characterization of minimal immunostimulatory CpG motifs...
  7. pmc Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells
    Jason D Marshall
    Dynavax Technologies Corporation, 717 Potter Street, Suite 100, Berkeley, CA 94710, USA
    Nucleic Acids Res 31:5122-33. 2003
    ....
  8. ncbi request reprint IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
    Omar Duramad
    Dynavax Technologies, 717 Potter St, Ste 100, Berkeley, CA 94710, USA
    Blood 102:4487-92. 2003
    ..The 3 distinct classes of ISS differed with respect to induction of PDC maturation and T-cell priming capacity. IL-10 regulated PDC activation but did not inhibit the subsequent T-cell-priming ability of PDCs already activated by ISS...
  9. ncbi request reprint Immunostimulatory DNA as a vaccine adjuvant
    Debbie Higgins
    Preclinical Research, Dynavax Technologies, 2929 Seventh Street, Suite 100, Berkeley, CA 94710, USA
    Expert Rev Vaccines 6:747-59. 2007
    ..To date, clinical testing has largely affirmed the potency and safety of ISS-adjuvanted vaccines...
  10. ncbi request reprint CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells
    Nicholas M Ponzio
    Department of Pathology and Laboratory Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School and Graduate School of Biomedical Sciences, Newark, NJ 07107, United States
    Int Immunopharmacol 6:2057-68. 2006
    ....